Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry

Dong Jin Park, Sungjae Choi, Kichul Shin, Hyoun Ah Kim, Yong Beom Park, Seong Wook Kang, Seung Ki Kwok, Seong Kyu Kim, Eon Jeong Nam, Yoon Kyoung Sung, Jaejoon Lee, Chang Hoon Lee, Chan Hong Jeon, Shin Seok Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for switching biologics in patients with RA. Patients with RA who had started on a biologic agent or had switched to another biologic agent were identified from the prospective observational Korean nationwide Biologics (KOBIO) registry. The KOBIO registry contained 1184 patients with RA at the time of initiation or switching of biologic agents. Patients were categorized according to the chronological order of the introduction of biologic agents, and reasons for switching biologics were also evaluated. Of the 1184 patients with RA, 801 started with their first biologic agent, 228 were first-time switchers, and 89 were second-time or more switchers. Second-time or more switchers had lower rheumatoid factor and anti-CCP positivity, and higher disease activity scores at the time of enrollment than the other groups. Among these patients, tocilizumab was the most commonly prescribed biologic agent, followed by adalimumab and etanercept. The most common reason for switching biologics was inefficacy, followed by adverse events, including infusion reactions, infections, and skin eruptions. Furthermore, the proportion of inefficacy, as a reason for switching, was significantly higher with respect to switching between biologics with different mechanisms of action than between biologics with similar mechanisms. In this registry, we showed diverse prescribing patterns and differing baseline profiles based on the chronological order of biologic agents.

Original languageEnglish
Pages (from-to)1013-1022
Number of pages10
JournalClinical Rheumatology
Volume36
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Biological Therapy
Biological Factors
Biological Products
Registries
Rheumatoid Arthritis
Population
Rheumatoid Factor
Quality of Health Care
Treatment Failure
Skin

Keywords

  • Biologic agents
  • Registry
  • Rheumatoid arthritis
  • Switching

ASJC Scopus subject areas

  • Rheumatology

Cite this

Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy : results from the KOBIO registry. / Park, Dong Jin; Choi, Sungjae; Shin, Kichul; Kim, Hyoun Ah; Park, Yong Beom; Kang, Seong Wook; Kwok, Seung Ki; Kim, Seong Kyu; Nam, Eon Jeong; Sung, Yoon Kyoung; Lee, Jaejoon; Lee, Chang Hoon; Jeon, Chan Hong; Lee, Shin Seok.

In: Clinical Rheumatology, Vol. 36, No. 5, 01.05.2017, p. 1013-1022.

Research output: Contribution to journalArticle

Park, DJ, Choi, S, Shin, K, Kim, HA, Park, YB, Kang, SW, Kwok, SK, Kim, SK, Nam, EJ, Sung, YK, Lee, J, Lee, CH, Jeon, CH & Lee, SS 2017, 'Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry', Clinical Rheumatology, vol. 36, no. 5, pp. 1013-1022. https://doi.org/10.1007/s10067-017-3584-y
Park, Dong Jin ; Choi, Sungjae ; Shin, Kichul ; Kim, Hyoun Ah ; Park, Yong Beom ; Kang, Seong Wook ; Kwok, Seung Ki ; Kim, Seong Kyu ; Nam, Eon Jeong ; Sung, Yoon Kyoung ; Lee, Jaejoon ; Lee, Chang Hoon ; Jeon, Chan Hong ; Lee, Shin Seok. / Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy : results from the KOBIO registry. In: Clinical Rheumatology. 2017 ; Vol. 36, No. 5. pp. 1013-1022.
@article{216aa3482c2c475380c01dc1a5a5db45,
title = "Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry",
abstract = "Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for switching biologics in patients with RA. Patients with RA who had started on a biologic agent or had switched to another biologic agent were identified from the prospective observational Korean nationwide Biologics (KOBIO) registry. The KOBIO registry contained 1184 patients with RA at the time of initiation or switching of biologic agents. Patients were categorized according to the chronological order of the introduction of biologic agents, and reasons for switching biologics were also evaluated. Of the 1184 patients with RA, 801 started with their first biologic agent, 228 were first-time switchers, and 89 were second-time or more switchers. Second-time or more switchers had lower rheumatoid factor and anti-CCP positivity, and higher disease activity scores at the time of enrollment than the other groups. Among these patients, tocilizumab was the most commonly prescribed biologic agent, followed by adalimumab and etanercept. The most common reason for switching biologics was inefficacy, followed by adverse events, including infusion reactions, infections, and skin eruptions. Furthermore, the proportion of inefficacy, as a reason for switching, was significantly higher with respect to switching between biologics with different mechanisms of action than between biologics with similar mechanisms. In this registry, we showed diverse prescribing patterns and differing baseline profiles based on the chronological order of biologic agents.",
keywords = "Biologic agents, Registry, Rheumatoid arthritis, Switching",
author = "Park, {Dong Jin} and Sungjae Choi and Kichul Shin and Kim, {Hyoun Ah} and Park, {Yong Beom} and Kang, {Seong Wook} and Kwok, {Seung Ki} and Kim, {Seong Kyu} and Nam, {Eon Jeong} and Sung, {Yoon Kyoung} and Jaejoon Lee and Lee, {Chang Hoon} and Jeon, {Chan Hong} and Lee, {Shin Seok}",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10067-017-3584-y",
language = "English",
volume = "36",
pages = "1013--1022",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "5",

}

TY - JOUR

T1 - Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy

T2 - results from the KOBIO registry

AU - Park, Dong Jin

AU - Choi, Sungjae

AU - Shin, Kichul

AU - Kim, Hyoun Ah

AU - Park, Yong Beom

AU - Kang, Seong Wook

AU - Kwok, Seung Ki

AU - Kim, Seong Kyu

AU - Nam, Eon Jeong

AU - Sung, Yoon Kyoung

AU - Lee, Jaejoon

AU - Lee, Chang Hoon

AU - Jeon, Chan Hong

AU - Lee, Shin Seok

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for switching biologics in patients with RA. Patients with RA who had started on a biologic agent or had switched to another biologic agent were identified from the prospective observational Korean nationwide Biologics (KOBIO) registry. The KOBIO registry contained 1184 patients with RA at the time of initiation or switching of biologic agents. Patients were categorized according to the chronological order of the introduction of biologic agents, and reasons for switching biologics were also evaluated. Of the 1184 patients with RA, 801 started with their first biologic agent, 228 were first-time switchers, and 89 were second-time or more switchers. Second-time or more switchers had lower rheumatoid factor and anti-CCP positivity, and higher disease activity scores at the time of enrollment than the other groups. Among these patients, tocilizumab was the most commonly prescribed biologic agent, followed by adalimumab and etanercept. The most common reason for switching biologics was inefficacy, followed by adverse events, including infusion reactions, infections, and skin eruptions. Furthermore, the proportion of inefficacy, as a reason for switching, was significantly higher with respect to switching between biologics with different mechanisms of action than between biologics with similar mechanisms. In this registry, we showed diverse prescribing patterns and differing baseline profiles based on the chronological order of biologic agents.

AB - Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for switching biologics in patients with RA. Patients with RA who had started on a biologic agent or had switched to another biologic agent were identified from the prospective observational Korean nationwide Biologics (KOBIO) registry. The KOBIO registry contained 1184 patients with RA at the time of initiation or switching of biologic agents. Patients were categorized according to the chronological order of the introduction of biologic agents, and reasons for switching biologics were also evaluated. Of the 1184 patients with RA, 801 started with their first biologic agent, 228 were first-time switchers, and 89 were second-time or more switchers. Second-time or more switchers had lower rheumatoid factor and anti-CCP positivity, and higher disease activity scores at the time of enrollment than the other groups. Among these patients, tocilizumab was the most commonly prescribed biologic agent, followed by adalimumab and etanercept. The most common reason for switching biologics was inefficacy, followed by adverse events, including infusion reactions, infections, and skin eruptions. Furthermore, the proportion of inefficacy, as a reason for switching, was significantly higher with respect to switching between biologics with different mechanisms of action than between biologics with similar mechanisms. In this registry, we showed diverse prescribing patterns and differing baseline profiles based on the chronological order of biologic agents.

KW - Biologic agents

KW - Registry

KW - Rheumatoid arthritis

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=85014053384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014053384&partnerID=8YFLogxK

U2 - 10.1007/s10067-017-3584-y

DO - 10.1007/s10067-017-3584-y

M3 - Article

C2 - 28243760

AN - SCOPUS:85014053384

VL - 36

SP - 1013

EP - 1022

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 5

ER -